| John Tivnan, DO | |
|
1365 Broadway, Bangor, ME 04401-2401 | |
| (207) 942-6226 | |
| (207) 992-2756 |
| Full Name | John Tivnan |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 8 Years |
| Location | 1365 Broadway, Bangor, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518315142 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP2900X | Anesthesiology - Pain Medicine | DO3257 (Maine) | Secondary |
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | DO3257 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Hospital | Bangor, ME | Hospital |
| Northern Light Maine Coast Hospital | Ellsworth, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Pain Management Pc | 1759355860 | 13 |
News Archive
A global analysis of brain proteins over a 10-week period in a mouse model of Huntington Disease has revealed some new insights into this complex neurodegenerative disorder.
The same mechanism that helps you detect bad-tasting and potentially poisonous foods may also play a role in protecting your airway from harmful substances, according to a study by scientists at the University of Iowa Roy J. and Lucille A. Carver College of Medicine.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported that based on a meeting held last week with the U.S. Food and Drug Administration (FDA), the Company plans to begin its Phase 3 program in December 2012 in support of a New Drug Application (NDA) for DSC127 for treatment of diabetic foot ulcers.
A visit to the doctor's office typically begins with a series of questions, including one about medications. An Iowa State University researcher recommends doctors ask a follow up to that question to make sure patients are taking their medications as prescribed.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.
› Verified 4 days ago
| Entity Name | Northeast Pain Management Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578579868 PECOS PAC ID: 1759355860 Enrollment ID: O20040824001047 |
News Archive
A global analysis of brain proteins over a 10-week period in a mouse model of Huntington Disease has revealed some new insights into this complex neurodegenerative disorder.
The same mechanism that helps you detect bad-tasting and potentially poisonous foods may also play a role in protecting your airway from harmful substances, according to a study by scientists at the University of Iowa Roy J. and Lucille A. Carver College of Medicine.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported that based on a meeting held last week with the U.S. Food and Drug Administration (FDA), the Company plans to begin its Phase 3 program in December 2012 in support of a New Drug Application (NDA) for DSC127 for treatment of diabetic foot ulcers.
A visit to the doctor's office typically begins with a series of questions, including one about medications. An Iowa State University researcher recommends doctors ask a follow up to that question to make sure patients are taking their medications as prescribed.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Tivnan, DO 1365 Broadway, Bangor, ME 04401-2401 Ph: (207) 942-6226 | John Tivnan, DO 1365 Broadway, Bangor, ME 04401-2401 Ph: (207) 942-6226 |
News Archive
A global analysis of brain proteins over a 10-week period in a mouse model of Huntington Disease has revealed some new insights into this complex neurodegenerative disorder.
The same mechanism that helps you detect bad-tasting and potentially poisonous foods may also play a role in protecting your airway from harmful substances, according to a study by scientists at the University of Iowa Roy J. and Lucille A. Carver College of Medicine.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported that based on a meeting held last week with the U.S. Food and Drug Administration (FDA), the Company plans to begin its Phase 3 program in December 2012 in support of a New Drug Application (NDA) for DSC127 for treatment of diabetic foot ulcers.
A visit to the doctor's office typically begins with a series of questions, including one about medications. An Iowa State University researcher recommends doctors ask a follow up to that question to make sure patients are taking their medications as prescribed.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.
› Verified 4 days ago
Dr. Brian E Kaufman, DO Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 1365 Broadway, Bangor, ME 04401 Phone: 207-942-6226 Fax: 207-992-2756 |